Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study

NCT ID: NCT01213810

Last Updated: 2013-03-01

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1/PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-12-31
• Study Completion Date: 2012-06-30

Brief Summary

The goal is to demonstrate the immunogenicity and safety of Zostavax® in HIV positive individuals. Study participants are stratified into different patient groups according to their CD4 cell count, viral load and HIV Status.

• Trial with medicinal product
• Trial with immunomodulatory product / biological

Conditions

Herpes Zoster

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Interventions

Zostavax

Biological/Vaccine

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Age >18 years
• Male, or female with negative urine pregnancy test
• VZV-seropositive (serologically documented)
• Agree to use a barrier method of birth control (such as a condom)
• Written informed consent HIV positive individuals on ART (group A1-A3)
• Continuous ART for >3 months before baseline
• No change of ART regimen within 1 month before baseline
• HIV-RNA (value must be <3 months old )<50 copies/ml at last visit
• CD4-count (value must be <3 months old) > 500 cells/µl for group A1, 350-500 cells/µl for group A2 and 250 -349 cells/µl for group A3
• Participation in the SHCS HIV-positive individuals without ART (group B)
• HIV-1 RNA >1000 copies/ml (<3 months before baseline)
• CD4-cell count >500 cells/µl (<3 months before baseline)
• Participation in the SHCS Healthy HIV-negative volunteers (group C)
• Negative HIV-screening test (<3 months before baseline)
• CD4 cell count >500 cells/µl

Exclusion Criteria

• Contraindications on ethical grounds
• Involvement in a conflicting (vaccine or investigational drug) clinical trial (except from the participation in the Swiss HIV Cohort Study).
• Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders or dementia of the subject.
• Pregnancy or breast feeding.
• Other clinically relevant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc),
• Known or suspected non-compliance, drug- or alcohol abuse.

• Fever > 38.3 °C or acute illness during the last 4 weeks
• Exposure to chickenpox or shingles within four weeks prior to study entry
• History of shingles
• Immunosuppression due to disease (other than HIV) or due to medication within 30 days of study entry (eg corticosteroids)
• Household contact with known immunodeficiency (e.g. HIV-positive with CD4 <250 cells/µl)
• Immunoglobulin or blood product treatment within 1 year prior or 2 month after study vaccination
• Previous allergic reaction to vaccine components (i.e. neomycin or gelatin)
• Vaccination with a life attenuated vaccine one month prior to study entry
• History of chickenpox vaccination
• Treatment with anti-herpes drugs 4 weeks before baseline
• Severe coagulation disorder or oral anticoagulant treatment

• Thrombocytopenia < 50x 103/?l
• Haemoglobin <12 g/dl
• More than threefold elevation of ALT
• Creatinine of more than150 µmol/l
• Glucose >10 mmol/l

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Zurich

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Barbara Hasse, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Zurich, Div of Infectious Diseases and Hospital Epidemiology

Other Identifiers

SHCS 610

Identifier Type: -

Identifier Source: org_study_id